Sep 30, 2026
Capricor Therapeutics (CAPR) Stock Surges on Extended Duchenne Treatment Data
Capricor (CAPR) stock rose after releasing 24-month deramiocel data from its Duchenne trial ahead of the FDA's November 22 decision deadline.
The post Capricor Therapeutics (CAPR) Stock Surges on Extended Duchenne Treatment Data appeared first on Blockonomi.
Source: Blockonomi →Related News
- 2 hours ago
Hyperliquid Strategies Inc. (PURR) Stock: Shares Climb as Company Boosts Buyback...
- 2 hours ago
Ionis Pharmaceuticals (IONS) Stock: Falls 2.23% Despite Roche’s Breakthrough Pha...
- 3 hours ago
Hyperscale Data, Inc. (GPUS) Stock: Soars 34% as Michigan AI Data Center Nears D...
- 4 hours ago
Edible Garden AG (EDBL) Stock Falls Despite New Farm Partnership Targeting 19% G...
- 7 hours ago
Rocket Lab (RKLB) Stock: Surges as Electron Completes 98th Launch for HawkEye 36...